

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Calabrese MD, Joseph R.		POSITION TITLE Director, Mood Disorders Program & Bipolar Disorder Across the Life Cycle Developing Center for Interventions and Services Research	
eRA COMMONS USER NAME JCALABRESE			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Xavier University	B.S.	1976	Biol., Summa Cum Laude
Ohio State University	M.D.	1980	Medicine
Cleveland Clinic Foundation		1984	Psychiatry
National Institute of Mental Health		1986	Biological Psych. Branch

A. Positions and Honors**Positions**

Psychiatry Resident	Cleveland Clinic Foundation	1981-1984
Chief Resident	Cleveland Clinic Foundation	1982-1984
Research Fellow	National Institute of Mental Health Neuroendocrinology, Biological Psychiatry Branch	1984-1986
Dir., Manic Depressive Clinic	Cleveland Clinic Foundation	1986-1989
Dir., Mood Disorders Program	University Hospitals of Cleveland Case Western Reserve Univ. School of Medicine	1989-Present
Professor of Psychiatry/with Tenure	Case Western Reserve Univ. School of Medicine	1996-Present
Principal Investigator	Bipolar Disorder Across the Life Cycle Developing Center for Interventions and Services Research	2003-Present

Honors

Cleveland Clinic Foundation, Department of Psychiatry, Teacher of the Year	1987
Cleveland Clinic Foundation, Department of Psychiatry, Teacher of the Year	1988
National Young Investigator Research Award, Nat'l Depressive Manic Depressive Assn.	1991
Case Western Reserve University, Department of Psychiatry, Teacher of the Year	1993
Dorothea Dix Humanitarian of the Year for work in Dual Diagnosis Bipolar disorder	2003
NARSAD Lifetime Achievement Award for Psychiatric Research in Mood Disorders	2004

B. Selected peer-reviewed publications

(selected from over 250 publications)

1. **Calabrese JR**, Gullledge AD, Hahn K, Skwerer RG, Gupta MK, Schumacher OP, Gold PW: Autoimmune thyroiditis in lithium-treated manic depression. *Am J Psychiatry* 1985; 142: 1318-1321.
2. **Calabrese JR**, Delucchi GA: Spectrum of efficacy of valproate in 55 rapid cycling manic depressives. *Am J Psychiatry*. 1990;147:431-434.
3. **Calabrese JR**, Fatemi SH, Kujawa MF, Woyshville MJ: Predictors of response to mood stabilizers. *J Clin Psychopharmacology* 1996; 16(2-Suppl 1): 24S-31S
4. Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, **Calabrese JR**, Goodnick P, Small JG, Rush J, Kimmel SE, Risch SC, Morris DD: Relationship of serum valproate concentration to response in mania. *Am J of Psychiatry* 1996; 153: 765-770.
5. **Calabrese, JR**, Goethe JW, Kayser A, Marcotte DB, Monagin JA, Kimmel SE, Brugger AM, Morris D, Fatemi SH: Adverse events in 583 valproate-treated patients. *Depression* 1996. 3(5): 257-262.
6. **Calabrese JR**, Maes M, Jayathilake K, Meltzer HY: Effects of Subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: Evidence for increased central serotonergic neurotransmission. *Psychiatry Research* 1997; 71(2): 67-76.

7. Bowden CL, **Calabrese JR**, McElroy SL, Rhodes LJ, Keck PE, Cookson J, Anderson J, Bolden-Watson C, Ascher J, Monaghan E: Comparison of the efficacy of lamotrigine in rapid cycling and non-rapid cycling bipolar disorder. *Biological Psychiatry*. 1999; 45: 953 – 958.
8. **Calabrese JR**, Bowden CL, McElroy SL, Cookson J, Andersen J, Rhodes L, Keck PE, Bolden-Watson C, Zhou J, Ascher J: Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. *Am J Psychiatry*. 1999; 156: 1019-1023.
9. **Calabrese JR**, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD for the Lamictal 602 Study Group: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. *J Clin Psychiatry* 1999; 60(2): 79-88.
10. **Calabrese JR**, Suppes T, Bowden CL, Kusumakar V, Sachs, GS, Swann AC, McElroy SL, Ascher JA, Earl NL, Greene PL, Monaghan ET for the Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder. *J Clin Psychiatry* 2000; 61: 841-50.
11. **Calabrese JR**, Rapport DJ, Shelton MD, Kimmel SE: Evolving methodologies in bipolar maintenance research. *Br J Psychiatry* 2001; 41(6): 157-63.
12. **Calabrese JR**, Shelton MD, Bowden CL, Rapport DJ, Suppes T, Shirley ER: Bipolar rapid cycling: Focus on depression as its hallmark. *J Clin Psychiatry* 2001; 62(14): 34-41.
13. Bowden CL, **Calabrese JR**, Sachs G, Yatham LN, Akthar-Asghar S, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeugh-Geiss J for the Lamictal 606 Study Group: A placebo-controlled 18 month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. *Arch Gen Psychiatry* 2003; 60(4): 393-400.
14. **Calabrese JR**, Bowden CL, Sachs G, Yatham L, Behnke K, Mehtonen O-P, Montgomery P, Ascher J, Paska W, Earl NL, DeVeugh-Geiss J for the Lamictal 605 Study Group: A placebo-controlled 18 month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. *J Clin Psychiatry* 2003; 64(9): 1013-1024.
15. Hirschfeld RMA, Holzer C, **Calabrese JR**, Weissman M, Reed M, Davies M, Frye MA, Keck P, McElroy S, Lewis L, Tierce J, Wagner KD, Hazard E: Validity of the Mood Disorders Questionnaire: A general population study. *American Journal of Psychiatry*. 2003 Jan;160(1):178-80.
16. **Calabrese JR**, Hirschfeld RMA, Reed M, Davies MA, Frye MA, Keck PE, Jr., Lewis L, McElroy SL, McNulty JP, Wagner KD: Impact of bipolar disorder on a U.S. community sample. *J Clin Psychiatry*. 2003 April; 64(4): 425-432.
17. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, **Calabrese J**, Kupfer D, Rosenbaum JF: Rationale, design, and methods of the systematic enhancement program for bipolar disorder. *Biol Psychiatry*. 2003 Jun 1; 53(11): 1028-42.
18. Muzina D, **Calabrese JR**: Recent-placebo-controlled acute trials of bipolar depression: Focus on methodology. *Int J Neuropsychopharmacol*. 2003 Sep;6(3):285-91.
19. **Calabrese JR**, Bowden CL, Sachs G, Yatham L, Behnke K, Mehtonen O-P, Montgomery P, Ascher J, Paska W, Earl NL, DeVeugh-Geiss J, for the Lamictal 605 Study Group: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. *J Clin Psychiatry*. 2003 Sept; 64(9):1013-1024.
20. Youngstrom EA, Gracious BL, Danielson CK, Findling RL, **Calabrese JR**: Toward an integration of parent and clinician report on the Young Mania Rating Scale. *J Affective Disorders*. 2003;77:179-90.
21. Tohen M, Vieta E, **Calabrese J**, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. *Arch Gen Psychiatry* 2003 Nov;60(11):1079-88.
22. Gracious BL, Findling RL, Seman C, Youngstrom EA, Demeter CA, **Calabrese JR**: Elevated TSH in bipolar youth prescribed both lithium and divalproex sodium. *J Am. Ac. Child Psychiatry*. 2004 Feb;43(2):215-220.
23. Swann AC, Daniel D, Kochan L, Wozniak P, **Calabrese JR**: Psychosis in mania: Specificity of its role in severity and treatment response. *J Clin Psychiatry*. 2004 Jun;65(6):825-829.
24. **Calabrese JR**, Hirschfeld RMA, Frye MA, Reed ML: Impact of depressive symptoms compared with manic symptoms in bipolar disorder. *J Clin Psychiatry* 2004 Nov;65(11):1499-1504.
25. **Calabrese JR**, Vieta E, El-Mallaki R, Findling RL, Youngstrom EA, Elhaj O, Pies R: Mood state at study entry as a predictor of risk of relapse and spectrum of efficacy in bipolar maintenance studies. *Biological Psychiatry* 2004 Dec 15; 56(12):857-73.
26. **Calabrese JR**, Keck PE, Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RG, Cutler AJ, McCoy R, Wilson E, Mullen J, for the Bolder Study Group: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. *Am J Psychiatry*. 2005;162:1351-1360.
27. Findling RL, McNamara NK, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD, **Calabrese JR**: A double-blind, 18-month trial of lithium vs. divalproex maintenance treatment in pediatric bipolar disorder. *J Am Ac Child & Adol Psychiatry* 2005;44(5)409-17.

28. Sajatovic M, Gyulai L, **Calabrese JR**, Thompson TR, Wilson BG, White R, Evoniuk G: Maintenance treatment outcomes in older patients with bipolar I disorder. *Am J Geriatr Psychiatry* 2005 Apr;13(4):305-11.
29. Hatters-Friedman S, Shelton MD, Elhaj O, Youngstrom EA, Rappoport DJ, Packer K, Bilali SR, Jackson KS, Sakai HE, Resnick PJ, Findling RL, **Calabrese JR**: Gender differences in criminality: Dual diagnosis bipolar disorder. *J American Academy of Psychiatry and Law*. 2005; 33(2): 183-187.
30. Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, **Calabrese JR**, Crisman ML, Ketter T, Sachs G, Swann AC: The Texas Implementation of Medication Algorithms: Update to the Algorithms for Treatment of Bipolar I Disorder. *J Clin Psychiatry*. 2005 Jul;66(7):870-86.
31. **Calabrese JR**, Shelton MD, Rappoport DJ, Youngstrom EA, Jackson K, Bilali S, Findling RL: A 20-month, double-blind, maintenance trial of lithium vs. divalproex in rapid cycling bipolar disorder. *Am J Psychiatry*. 2005 Nov;162:2152-2161.
32. Frye MA, **Calabrese JR**, Reed M, Weissman MM, Wagner KD, Lewis L, McNulty J, Hirschfeld RMA: Health services utilization in a population based sample who screening positive for bipolar disorder. *Psychiatric Services*. 2005 Dec;56(12):1529-1533.
33. Mansour HA, Talkowski ME, Wood J, Bamne M, Chowdari KV, Allen M, Bowden CL, **Calabrese J**, El-Mallakh RS, Fagiolini A, Fossey MD, Friedman E, Gyulai L, Hauser P, Loftis J, Marangell L, Miklowitz D, Nierenberg AA, Patel J, Sachs G, Smoller J, Thase M, Frank E, Kupfer DJ, Nimgaonkar VL: Serotonin Gene Polymorphisms and Bipolar I Disorder: Focus on the Serotonin Transporter. *Annals of Medicine*. 2005 Dec 1;37(8):590-602.
34. Goldberg JF, Allen MH, Miklowitz DA, Bowden CL, Endick CJ, Chessick CA, Wisniewski SR, Miyahara S, Sagduyu K, Thase ME, **Calabrese JR**, Sachs GS: Suicidal Ideation and pharmacotherapy among STEP-BD Patients. *Psychiatr Serv*. 2005 Dec;56(12):1534-1540
35. Findling RL, Youngstrom EA, McNamara NK, Stansbrey RS, Demeter CA, Bedoya D, Kahana SY, **Calabrese JR**: Early symptoms of mania and the role of parental risk. *Bipolar Disorders*. 2005 dec;7(6):623-34.
36. Youngstrom EA, Meyers O, Demeter C, Youngstrom J, Morello Simonitis L, Piiparinen R, Feeny N, **Calabrese JR**, Findling RL: Comparing diagnostic checklists for pediatric bipolar disorder in academic and community mental health settings. *Bipolar Disorders*. 2005 Dec;7(6):507-17.
37. Allen MH, Chessick CA, Miklowitz DJ, Goldberg JF, Wisniewski SR, Miyahara S, **Calabrese JR**, Marangell L, Bauer MS, Thomas MR, Bowden CL, Sachs GS: Contributors to suicidal ideation among bipolar patients with and without a history of suicide attempts. *Suicide Life Threat Behavior*. 2005 Dec;35(6):671-80.
38. Findling RL, McNamara NK, Stansbrey R, Gracious BL, Whipkey RE, Demeter CA, Youngstrom EA, **Calabrese JR**: Combination lithium and divalproex sodium in pediatric bipolar symptom restabilization. *J Am Acad Child Adolesc Psychiatry* 2006 Feb;45(2):142-148.
39. Nierenberg AA, Ostacher MJ, **Calabrese JR**, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS: Treatment-resistant bipolar depression: a STEP-BD equipose randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. *Am J Psychiatry*. 2006 Feb;163(2):210-6.
40. Tohen M, **Calabrese JR**, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL: Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. *Am J Psychiatry*. 2006 Feb;163(2):247-56.
41. Sachs G, Bowden C, **Calabrese JR**, Ketter T, Thompson T, White R, Bentley B: Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. *Bipolar Disord*. 2006 Apr;8(2): 175-81.
42. Keck PE Jr, **Calabrese JR**, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R; Aripiprazole Study Group: A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. *J Clin Psychiatry*. 2006 Apr;67(4):626-37.
43. **Calabrese JR**, Goldberg JF, Ketter TA, Suppes T, Frye M, White R, DeVeaugh-Geiss A, Thompson TR: Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. *Biol Psychiatry*. 2006 June 1;59(11):1061-4.
44. Shim SS, Hammonds MD, Ganocy SJ, **Calabrese JR**: Effects of sub-chronic lithium treatment on synaptic plasticity in the dentate gyrus of rat hippocampus slices. *Prog Neuropsychopharmacol Biol Psychiatry* 2006 Nov 8; [Epub ahead of print]
45. Bowden CL, **Calabrese JR**, Ketter TA, Sachs GS, White RL, Thompson TR: Impact of lamotrigine and lithium on weight in obese and non-obese patients with bipolar I disorder. *Am J Psychiatry*. 2006 Jul;163(7):1199-201.
46. Kubota Y, Toichi M, Shimizu M, Mason RA, Findling RL, Yamamoto K, **Calabrese JR**: Prefrontal hemodynamic activity predicts false memory-A near-infrared spectroscopy study. *Neuroimage*. 2006 Jul 15;31(4):1783-9.
47. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, **Calabrese JR**: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study. *J Clin Psychopharmacol*. Dec;26(6):600-9.
48. Tohen M, Bowden CL, **Calabrese JR**, Lin D, Forrester TD, Sachs GS, Koukopoulos A, Yatham L, Grunze H: Influence of sub-syndromal symptoms after remission from manic or mixed episodes. *Br J Psychiatry*. 2006 Dec;189:515-9.

49. Frye MA, Yatham LN, **Calabrese JR**, Bowden CL, Ketter TA, Suppes T, Adams BE, Thompson TR: Incidence and time course of sub-syndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J Clin Psychiatry 2006 Nov;67(11):1721-8.

C. Research Support

Ongoing Research Support

P20 – MH066054 (Principal Investigator – 45%)

NIMH

9/1/2003 – 6/30/2008

Bipolar Disorder Across the Life Span

The primary objective of this developing Center is the conduct of studies designed to improve clinical outcomes in underserved populations of bipolar disorder, including those receiving care within community mental health centers, children and adolescents, and adults currently abusing alcohol and/or drugs.

K23 (Mentor) (PI – Martha Sajatovic MD)

NIMH K 23-MH0655997

9/12/2003 – 8/31/2008

Bipolar Disorder, Subjectivity and Treatment Adherence.

A mentored patient-oriented research career development award focused on examining the relationship between the subjective experiences of patients with bipolar disorder and the impact of other factors (e.g., symptoms, gender, social support, substance) on treatment adherence. Dr. Calabrese's role as co-mentor focuses on training in design and implementation of studies in bipolar disorder.

Extension of contract N01MH80001 (Systematic Treatment Enhancement Program for Bipolar Disorders (STEP-BD) (Case Western Reserve University Site Director – 10%) (Director: Andrew A. Nierenberg, MD; Co-Director: Lauren Marangell, MD

NIMH

11/1/2005 – 9/30/06

Bipolar Trials Network

This project will be used to maintain a clinic registry database that includes contact information and relevant demographic and clinical variables. New patients who enter the Mood Disorders Program will also be tracked and the National Coordinating Center will maintain a de-identified database to track the overall characteristics of patients for all sites. IRB permission will be obtained for the pilot registry. Process and informed consent obtained. Efforts will also be made within the limits of the budget for each site to keep their clinic patients informed of new protocols through the use of newsletters, postcards, postings on websites, etc.

Resilience and Risk Factors Associated With Combat-related Posttraumatic Psychopathology

U.S. Department of Defense (Principal Investigator – 35%)

2/8/07 – 12/31/20

This project represents the first effort in a series of proposed research projects designed to evaluate the phenomenology and treatment of serious mental illness, as well as normal post-deployment readjustment issues, as they impact on military personnel and veterans, as well as the families of service members, and the promotion of 'resilience' as it relates to combat-related stress associated with deployment of the guard and reserve.